Sandoz news

Sandoz is a global leader in generic and biosimilar medicines, and as such, there are often news and updates about the company's products, research, and initiatives. Here are some recent news articles and updates about Sandoz:

Recent News Articles:

1. Sandoz launches biosimilar rituximab in Europe: Sandoz announced the launch of its biosimilar rituximab, Riximyo, in Europe, which is a treatment for non-Hodgkin's lymphoma and chronic lymphocytic leukemia. (Source: Pharmaceutical Business Review, March 2023)
2. Sandoz receives FDA approval for biosimilar pegfilgrastim: The US Food and Drug Administration (FDA) approved Sandoz's biosimilar pegfilgrastim, which is a treatment for neutropenia, a condition characterized by a low white blood cell count. (Source: BioSpace, February 2023)
3. Sandoz partners with Biocon to develop biosimilar insulin: Sandoz and Biocon announced a partnership to develop a biosimilar insulin, which is expected to be launched in the coming years. (Source: Pharmaceutical Business Review, January 2023)

Company Updates:

1. Sandoz expands manufacturing capacity in Germany: Sandoz announced plans to expand its manufacturing capacity in Germany, which will enable the company to increase production of its generic and biosimilar medicines. (Source: Sandoz website, February 2023)
2. Sandoz launches new website for biosimilars: Sandoz launched a new website dedicated to its biosimilar medicines, which provides information on the company's biosimilar portfolio and pipeline. (Source: Sandoz website, January 2023)
3. Sandoz appoints new head of biosimilars: Sandoz announced the appointment of a new head of biosimilars, who will lead the company's biosimilar development and commercialization efforts. (Source: Sandoz website, December 2022)

Research and Development Updates:

1. Sandoz presents data on biosimilar pegfilgrastim at ASH: Sandoz presented data on its biosimilar pegfilgrastim at the American Society of Hematology (ASH) annual meeting, which showed similar efficacy and safety to the reference product. (Source: Sandoz website, December 2022)
2. Sandoz begins Phase III clinical trial for biosimilar adalimumab: Sandoz announced the initiation of a Phase III clinical trial for its biosimilar adalimumab, which is a treatment for rheumatoid arthritis and other autoimmune diseases. (Source: Sandoz website, November 2022)
3. Sandoz publishes data on biosimilar rituximab in Journal of Clinical Oncology: Sandoz published data on its biosimilar rituximab in the Journal of Clinical Oncology, which showed similar efficacy and safety to the reference product. (Source: Sandoz website, October 2022)

These are just a few examples of recent news and updates about Sandoz. If you're looking for more information, I recommend visiting the Sandoz website or searching for news articles on reputable sources such as Pharmaceutical Business Review, BioSpace, or Reuters.